Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Brett Fishbin
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q3 (9 quarters).
- Questions
- 40on tracked calls
- Challenge rate
- 3%1 of 40 questions
- Companies
- 4questioned at least once
- Reporting periods
- 9with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 40 of 40 questions from 4 companies
STESteris15 questions · 8 reporting periods · 0 of 15 challenging
Calendar 2026 Q2
I think I caught, you might have said something about share gains in endoscopy. Maybe if you could just expand a little bit, where in the portfolio you're seeing the gains.
Show response
Dan detailed share gains in endoscopy across automatic endoscope reprocessors, dedicated chemistries, and repair services for endoscopes and instruments.
the other part of the business that was a little bit slower this quarter in healthcare capital equipment. I know you mentioned timing and the backlog number looked pretty strong still.
Show response
Dan characterized the capital equipment softness as pure shipment timing, expressing high confidence in solid full-year capital growth and pull-through into consumables, chemistry, and services.
Just wanted to ask a little bit about the underlying trends in AST service. I know you've talked about a progression in growth through the year given the tough 1H comps and inventory dynamics.
Show response
Dan reaffirmed the modeled second-half acceleration in AST as easier comparisons arrive in Q3, noting nothing has changed in the fundamentals after a strong 13% first-half last year.
Calendar 2026 Q1
I was just curious if you could walk through like some of the moving pieces. I think there are some questions around the impact of inflation and energy prices
Show response
Dan and Karen provided thorough breakdown of margin drivers: operational improvements, consumables mix, AST upside potential, tariff favorability, $2M bonus tailwind, and measured energy assumptions.
I just wanted to maybe ask more broadly how you're thinking about overall phasing for organic growth, whether you're calling for like a softer 1Q overall?
Show response
Dan clarified the softness is AST-specific, expecting slower first half due to tough comps and then significant improvement in Q3 and easy comps in Q4.
Calendar 2025 Q4
I was just interested to hear maybe a little bit more about what you're seeing around capital equipment backlog activity in both segments
Show response
Dan attributed LS backlog growth to recovery from pharma downcycle with strong order intake continuing. Healthcare backlog stable at $400M+ with orders down only 1% against a blowout prior year. Called STERIS products a 'utility' essential for hospital capacity.
Just was hoping maybe at a high level, company-wide, you could just touch on how you're thinking about fourth-quarter constant currency growth
Show response
Karen cautioned against extrapolating H1 strength into Q4, citing tough comps especially in AST capital equipment. Julie added Healthcare services expected to continue slowing from 11% in Q3.
Calendar 2025 Q3
I was curious if you guys could comment a little bit on what drove the second consecutive quarter of double-digit growth in services
Show response
Dan cited stable medtech volumes, bioprocessing recovery, and 4 years of expansion investments coming online. Expressed confidence in 9-10% outlook.
Maybe if you could just touch on any other items that you might have been referring to
Show response
Karen quantified the two headwinds precisely: tariffs 90bp and material/labor inflation 130bp company-wide in Q2.
Calendar 2025 Q2
if you could just give a little bit more detail on specifically what drove the increased expectation
Show response
Mike attributed the $15M increase to specific metals tariff escalations since May guidance, noting STERIS had more initial clarity than most peers.
Calendar 2025 Q1
do you have enough capacity to theoretically return to double-digit growth in AST service
Show response
Dan confirmed capacity is not a limiting factor for AST growth. The company has sufficient capacity to accommodate industry growth.
how like some of the recent macro developments have impacted like either ordering patterns or like hospitals' willingness
Show response
Dan emphasized STERIS products are utilities essential for procedural capacity, not discretionary. Order growth of 12%, backlog strong, no slowdown seen.
Calendar 2024 Q4
could you help frame how you're viewing the potential risk in the scenario that tariffs are, in fact, reintroduced
Show response
Mike declined to comment directionally on tariff impact but provided a key data point: Canadian and Mexican facilities represent just under 10% of COGS.
Calendar 2024 Q3
I was really just hoping if you could parse that out a little bit, maybe between progress year-to-date versus where you thought you'd be
Show response
Dan minimized the capital equipment revision, citing weather-related delays and noting the shortfall is offset by higher-profit consumables and services.
Is the change in language really just tied to the pace of call it, sequential improvement at AST and the favorable revenue mix
Show response
Mike confirmed margin flat outlook is solely AST-driven and stated nothing else would stop them from achieving long-term EBIT margin expansion goals.
COOCooper Companies (The)12 questions · 8 reporting periods · 0 of 12 challenging
Calendar 2026 Q3
how active the R&D pipeline might be in regards to some new ideas or even new brands.
Show response
Al said Cooper is accelerating R&D and pulling forward product launches previously targeted for around 2030 to reinvigorate the CVI portfolio.
Calendar 2026 Q2
how much of the improvement was really driven by some of the durable changes in cost structure
Show response
Al credited the operating margin gain mainly to CooperSurgical back-office leverage plus corporate cost leverage and a temporary FX benefit.
Calendar 2026 Q1
Are there 1 or 2 of these that you would call out as maybe the most exciting to you in terms of like just what they can do for company growth
Show response
Most exciting product launches for FY2026 growth impact. Management responded with context on this topic.
I was just hoping you could unpack a little bit in terms of what went better than you thought and why you were able to call the operating margins as exceeding expectations
Show response
Q1 operating margin beat drivers, AI and reorganization synergies. Management responded with context on this topic.
Calendar 2025 Q4
was hoping you could just update whether that had any impact on 4Q either negative or if there was some positive reversion.
Show response
Distributor channel inventory impact in Q4 and FY2026 neutrality. Management responded with context on this topic.
maybe just touch on how you're thinking about the longer term opportunity in that region. And then just, you know, coming back specifically to what's expected in the FY '26 guide.
Show response
MiSight Japan launch opportunity sizing and FY2026 guide impact. Management responded with context on this topic.
Calendar 2025 Q3
You mentioned that you won some new private label agreements. And was just curious if you could maybe expand a little bit on some of those wins
Show response
New private label agreements detail and FY2026 upside potential. Management responded with context on this topic.
it sounded like the early results were mixed. So just curious where maybe you saw some initial success or lack of success
Show response
MiSight promotional pricing early results, mixed in Americas. Management responded with context on this topic.
Calendar 2025 Q2
Just wanted to ask if you could expand a little bit on what you're seeing around broader demand for Toric and multifocals. It seems like we got into, like, a pretty steady cadence of double digit g...
Show response
Toric and multifocal growth deceleration to 7% from double digits. Management responded with context on this topic.
Calendar 2025 Q1
first time that there has been a new entrance into this market in a really long time. So just curious if you could touch on maybe any changes in strategy you would be considering
Show response
PARAGARD competitive strategy changes with new market entrant. Management responded with context on this topic.
Calendar 2024 Q4
how sizable the Energys product lines have become just thinking about the CVI business as a whole
Show response
How sizable has the Energys product line become for CVI. Management responded with context on this topic.
I think you mentioned 40% growth expectation for FY'25. And I was just curious how you're thinking about the contribution from the U.S. versus some of the international markets
Show response
MiSight 40% growth drivers: U.S. vs international contribution. Management responded with context on this topic.
SOLVSolventum7 questions · 4 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
one metric that stood out was just a very high level of growth from Acera.
Show response
Bryan credited Acera's differentiated Restrata synthetic-tissue technology and shared customer relationships, expecting continued double-digit growth; Wayde walked through the guide-raise math.
Calendar 2026 Q1
is there any reason to think that the ex-ERP benefit run rate would not be somewhere within the 2% to 3% current guidance range
Show response
CFO confirmed underlying momentum should continue through the year; not giving quarterly guidance but strong Q1 carries forward.
Could you flesh out where you expect to see the benefit relative to the different segments in Q2 from a modeling perspective
Show response
CFO confirmed $100M+ Q2 pre-buy concentrated in IPSS and Dental; U.S. distribution model enables stocking distributors ahead of Q3 ERP cutover; will reverse mostly in Q3.
Calendar 2025 Q4
I was curious if you could just directionally provide any commentary on how you're thinking about that across the different segments
Show response
CFO noted SKU impact concentrated in MedSurg/IPSS; all segments expected to improve underlying growth YoY; midpoint continuation of 2025 momentum, high end touches LRP low end.
I was hoping you could just touch on your decision to implement a Chief Commercial Officer position
Show response
CEO explained new CCO Heather was continuation of plan to combine businesses under one leader; prior executive exited for personal reasons; new hire brings strong operational and transformation experience.
Calendar 2025 Q2
if you're willing to touch on any new products or general areas that we should be looking out for in that segment or in the rest of the business in 2H
Show response
CEO highlighted existing launches (Clinpro Clear, Filtek Easy Match, Clarity Precision Grip) building momentum but declined to preview unannounced products.
I was just curious if you could maybe touch on how you're viewing the underlying patient trends in the Dental Solutions business
Show response
CEO noted dental market not accelerating or decelerating; company growth not dependent on market improvement, driven instead by new products and specialized sales.
RMDResMed6 questions · 6 reporting periods · 1 of 6 challenging
Calendar 2026 Q2
How does the 130 basis point expected headwind for the year relate to the EPS guidance?
Show response
Aaron sized the Astral drag at about 15¢ EPS (lost revenue flowing to lost gross margin), embedded in the 12 to 14% core EPS growth guide.
Calendar 2025 Q3
the 1 area to maybe nitpick was just the mid-single-digit growth trend in SaaS which is a little bit below your typical levels
Show response
Mick explained portfolio restructuring: investing in core SaaS (MEDIFOX, Brightree, MatrixCare home health) while reducing lower-margin services businesses. Expects mid-to-high single digit growth in H2 FY2026 and sustainable high single-digit growth with double-digit NOP growth in 12 months.
Calendar 2025 Q2
61% to 63% represents 200 bps year-over-year at the midpoint and 300 bps at the high end
Show response
Brett outlined phasing: start at lower end of 61-63% and exit FY2026 at higher rate. Drivers: procurement initiatives, manufacturing cycle time improvements, scale benefits, logistics efficiencies, AS10-to-AS11 transition, favorable product mix, and new product introductions.
Calendar 2025 Q1
was hoping if you could maybe expand on what some of the key initiatives in those buckets have been like, where you're seeing the most impact
Show response
Brett highlighted sea-to-air freight ratio nearly back to pre-COVID levels as a strong driver. Manufacturing efficiencies from mature AS10/AS11 platforms and continuous improvement programs. Scale benefits amplify small improvements.
Calendar 2024 Q4
Are you still expecting a sequential increase given relatively flat performance in 2Q versus 1Q?
Show response
Brett confirmed 59-60% range guidance. Key swing factors: manufacturing optimization, procurement, AS11 transition benefits, product mix, and freight stabilization.
Calendar 2024 Q3
if you could maybe touch on a few potential strategies that the company could be looking at
Show response
Mick outlined three-pronged strategy: demand generation (big tech/pharma driving awareness), demand capture (Dawn AI, Somnoware), and demand conversion (digital sleep health concierge).
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| STE Steris | 15 | 0%none of 15 questions |
| COO Cooper Companies (The) | 12 | 0%none of 12 questions |
| SOLV Solventum | 7 | 0%none of 7 questions |
| RMD ResMed | 6 | 17%1 of 6 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q3 | 3 | 0%none of 3 questions | 2 |
| 2024 Q4 | 4 | 0%none of 4 questions | 3 |
| 2025 Q1 | 4 | 0%none of 4 questions | 3 |
| 2025 Q2 | 5 | 0%none of 5 questions | 4 |
| 2025 Q3 | 5 | 20%1 of 5 questions | 3 |
| 2025 Q4 | 6 | 0%none of 6 questions | 3 |
| 2026 Q1 | 6 | 0%none of 6 questions | 3 |
| 2026 Q2 | 6 | 0%none of 6 questions | 4 |
| 2026 Q3 | 1 | 0%none of 1 question | 1 |
- 2024 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2024 Q44 questions · challenge rate 0% (none of 4 questions) · 3 companies
- 2025 Q14 questions · challenge rate 0% (none of 4 questions) · 3 companies
- 2025 Q25 questions · challenge rate 0% (none of 5 questions) · 4 companies
- 2025 Q35 questions · challenge rate 20% (1 of 5 questions) · 3 companies
- 2025 Q46 questions · challenge rate 0% (none of 6 questions) · 3 companies
- 2026 Q16 questions · challenge rate 0% (none of 6 questions) · 3 companies
- 2026 Q26 questions · challenge rate 0% (none of 6 questions) · 4 companies
- 2026 Q31 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Revenue Growth14
- Demand12
- Product Launch10
- Margin9
- Cost Pressure6
- Competitive Dynamics5
- Innovation & R&D4
- Trade Tariffs3
- Inventory2
- Guidance Reliability2
Show all 17 topics
- Supply Chain2
- Geographic Expansion2
- Macroeconomic2
- M&A1
- Cloud & AI1
- Capex Investment1
- Pricing1